Reports
Sale
Global Chronic Inflammatory Demyelinating Polyneuropathy Treatment Market Share, Size, Trends, Analysis, Growth, Forecast: By Therapeutic Method: Corticosteroids, Intravenous Immunoglobulin, Plasma Exchange, Immunotherapy, Others; By Diagnosis; By Route of Administration; By End User; Regional Analysis; Supplier Landscape; 2024-2032
Global Chronic Inflammatory Demyelinating Polyneuropathy Treatment Market Outlook
The chronic inflammatory demyelinating polyneuropathy treatment market attained a value of USD 3.61 billion in 2021. The market is expected to rise at a CAGR of 6.90% in the forecast period of 2024-2032 and is anticipated to be worth USD 6.91 billion by 2030.
Chronic Inflammatory Demyelinating Polyneuropathy: Disease Insights
Chronic inflammatory demyelinating polyneuropathy is a rare neuroinflammatory disorder. The destruction of nerve fibre myelin sheaths and inflammation of nerve roots takes place in this disorder. The reduction of myelin causes nerve signals blockage and thus, substantial loss in the nerve fibres.
The severity of the disease, duration of disease and symptoms vary from patient to patient. The common signs and symptoms of chronic inflammatory demyelinating polyneuropathy are impaired body movements, weakness of both muscles and paralysis in extreme cases. The disfigurement in the motor and sensory functions affects both sides of the body.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
There are different variants of chronic inflammatory demyelinating polyneuropathy such as multifocal variants, pure sensory variants, distal variants, and pure motor variants. The exact cause of CIDP is still not clear, but the studies suggest, it to be an autoimmune disorder.
The diagnosis of chronic inflammatory demyelinating polyneuropathy is a bit complicated, due to the very common symptoms. Electromyography is the primary test used to analyse the velocities of nerve conduction. Lumbar puncture and MRI imaging are the additional diagnostic tests of CIDP. These tests help in the detection of enlargement and indications of pain.
Several approved treatments are used for the management of chronic inflammatory demyelinating polyneuropathy.
According to the chronic inflammatory demyelinating polyneuropathy treatment market research report, the market can be categorised into the following segments:
Market Breakup by Therapeutic Method
- Corticosteroids
- Intravenous Immunoglobulin
- Plasma exchange
- Immunotherapy
- Stem Cell Transplant
- Physical therapy
- Others
Market Breakup by Diagnosis
- Electrodiagnostic Testing
- Nerve Conduction
- Electromyography
- Spinal Fluid Analysis
- Others
Market Breakup by Route of Administration
- Intravenous
- Oral
- Others
Market Breakup by End User
- Hospitals
- Specialty Neurological Clinics
- Research and Academic Laboratories
Market Breakup by Region
- North America
- United States of America
- Canada
- Europe
- United Kingdom
- Germany
- France
- Italy
- Others
- Asia Pacific
- China
- Japan
- India
- ASEAN
- Australia
- Others
- Latin America
- Brazil
- Argentina
- Mexico
- Others
- Middle East and Africa
- Saudi Arabia
- United Arab Emirates
- Nigeria
- South Africa
- Others
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Market Scenario
The increasing incidence and prevalence of CIDP are driving the growth of the chronic inflammatory demyelinating polyneuropathy treatment market. According to National Organisation for Rare Disorders, every 5-7 individuals per 100,000 are diagnosed with CIDP. The rising cases of CIDP are propelling the demand for the treatment market.
The growing research and development activities will lead to the discovery of novel targeted therapies. At present, according to clinicaltrials.gov, more than thirty-eight clinical trials are under current evaluation.
The CIDP organisations and international support groups are creating awareness regarding the diagnosis and treatment of CIDP. Raising awareness and support initiatives have stimulated the growth of the market.
With technological advancements, there are innovations in diagnostic tools and interventions. This will assist in more specific and accurate detection. The advancements in diagnostic techniques are also aiding the growth of the market.
North America Accounts for the Largest Share
North America is anticipated to hold the maximum share in the CIDP market. Increased expenditure in the healthcare sector and greater research and developmental activities are driving the growth of the chronic inflammatory demyelinating polyneuropathy treatment market.
Therapeutic Landscape
There are multiple therapeutic strategies approved for the management of chronic inflammatory demyelinating treatment. The available treatments suppress the immune system and thus, there are high chances of infections and other related disorders.
Standard Therapies: Corticosteroids, Immunoglobins, Plasma Exchange and Immunosuppressants are Aiding the Growth of the Market
Glucocorticosteroids are the first-line medications for treating CIDP. These drugs are used in combination with other immunosuppressive drugs to provide more efficient treatment. Prednisone is one of the most common drugs belonging to this category.
Intravenous immunoglobin has also shown promising effects in the treatment of CIDP. This therapy increases immunity and assists in the treatment. Subcutaneous immunoglobin delivery is an alternative form of IVIG therapy.
Plasma Exchange is the chronic treatment for the management of chronic inflammatory demyelinating polyneuropathy. In this therapeutic procedure, immunoglobins and other components are extracted from the immunity system. The plasma and its constituents are also removed from the affected individual and then replaced with albumin. The blood cells are transfused back into the patient.
Immunosuppressive agents are also used for treating chronic inflammatory demyelinating polyneuropathy. Some examples of such agents are mycophenolate, cyclosporine, and azathioprine. The discovery of novel immunosuppressants is anticipated to fuel the chronic inflammatory demyelinating polyneuropathy treatment market growth.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Clinical Trial Landscape
With the increase in disease prevalence, there is a need for novel therapeutic interventions. These new treatments are anticipated to provide lucrative opportunities in the therapeutic sector.
Emerging Therapies: Monoclonal Antibodies, FcRN Inhibitors, and HYQVIA Therapy
The clinical trials for the incorporation of monoclonal antibodies in the standard treatments are under evaluation. Monoclonal antibodies are artificially made proteins resembling the immune system’s pathogenic defence mechanism.
Rituximab, a monoclonal antibody has recently been approved by the USFDA for the treatment of multiple sclerosis and rheumatoid arthritis.
The investigation for reducing circulating immunoglobins is also under process. These studies incorporate the activity of FcRN inhibitors that will assist in the management of chronic inflammatory demyelinating polyneuropathy.
Takeda, a key player is performing the final stage of clinical trials for a recombinant therapy HYQVIA. This therapy incorporates human hyaluronidase with a ten per cent infusion of human immunoglobins. The company aims to get approvals from the USFDA and EMA by the end of 2023. If approved, this can be used as maintenance therapy for alleviating the symptoms of chronic inflammatory demyelinating polyneuropathy.
Implementing advanced technologies in healthcare has already provided enormous benefits to human health. Researchers’ tremendous efforts have anticipated a rapid increase in the approvals for recombinant therapies. Several ongoing clinical trials are emerging as a driving factor for the market growth and development.
Competitive Landscape
The report gives an in-depth analysis of the key players involved in the chronic inflammatory demyelinating polyneuropathy treatment market, sponsors manufacturing the therapies, and putting them through trials to get FDA approvals. The companies included in the market are as follows:
- Grifols, S.A.
- Octapharma AG
- Baxter International Inc.
- Pfizer Inc.
- CSL Behring LLC
- MedDay SA
- Shire plc
- Takeda Pharmaceutical Company Limited
- Teijin Limited
- Momenta Pharmaceuticals, Inc.
Key Highlights of the Report
| REPORT FEATURES | DETAILS |
|---|---|
| Base Year | 2023 |
| Historical Period | 2017-2023 |
| Forecast Period | 2024-2032 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Therapeutic Method |
|
| Breakup by Diagnosis |
|
| Breakup by Route of Administration |
|
| Breakup by End User |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
2 Research Methodology
3 Executive Summary
4 Chronic Inflammatory Demyelinating Polyneuropathy Overview
4.1 Guidelines and Stages
4.2 Pathophysiology
4.3 Screening and Diagnosis
4.4 Treatment Pathway
5 Patient Profile
5.1 Patient Profile Overview
5.2 Patient Psychology and Emotional Impact Factors
5.3 Risk Assessment and Treatment Success Rate
6 Global Chronic Inflammatory Demyelinating Polyneuropathy Treatment Market
6.1 Global Chronic Inflammatory Demyelinating Polyneuropathy Treatment Market Overview
6.2 Global Chronic Inflammatory Demyelinating Polyneuropathy Treatment Market Analysis
6.2.1 Market Overview
6.2.1.1 Global Historical Chronic Inflammatory Demyelinating Polyneuropathy Treatment Market Value (2017-2023)
6.2.1.2 Global Forecast Chronic Inflammatory Demyelinating Polyneuropathy Treatment Market Value (2024-2032)
6.3 Global Chronic Inflammatory Demyelinating Polyneuropathy Treatment Market by Therapeutic Method
6.3.1 Market Overview
6.3.1.1 Corticosteroids
6.3.1.2 Intravenous Immunoglobulin
6.3.1.3 Plasma Exchange
6.3.1.4 Immunotherapy
6.3.1.5 Stem Cell Transplant
6.3.1.6 Physical Therapy
6.3.1.7 Others
6.4 Global Chronic Inflammatory Demyelinating Polyneuropathy Treatment Market by Diagnosis
6.4.1 Market Overview
6.4.1.1 Electrodiagnostic Testing
6.4.1.2 Nerve Conduction
6.4.1.3 Electromyography
6.4.1.4 Spinal Fluid Analysis
6.4.1.5 Others
6.5 Global Chronic Inflammatory Demyelinating Polyneuropathy Treatment Market by Route of Administration
6.5.1 Market Overview
6.5.1.1 Intravenous
6.5.1.2 Oral
6.5.1.3 Others
6.6 Global Chronic Inflammatory Demyelinating Polyneuropathy Treatment Market by End User
6.6.1 Market Overview
6.6.1.1 Hospitals
6.6.1.2 Specialty Neurological Clinics
6.6.1.3 Research and Academic Laboratories
6.7 Global Chronic Inflammatory Demyelinating Polyneuropathy Treatment Market by Region
6.7.1 Market Overview
6.7.1.1 North America
6.7.1.2 Europe
6.7.1.3 Asia Pacific
6.7.1.4 Middle East and Africa
6.7.1.5 Latin America
7 North America Chronic Inflammatory Demyelinating Polyneuropathy Treatment Market
7.1 Market Share by Country
7.2 United States of America
7.2.1 Historical Trend (2017-2023)
7.2.2 Forecast Trend (2024-2032)
7.3 Canada
7.3.1 Historical Trend (2017-2023)
7.3.2 Forecast Trend (2024-2032)
8 Europe Chronic Inflammatory Demyelinating Polyneuropathy Treatment Market
8.1 Market Share by Country
8.2 United Kingdom
8.2.1 Historical Trend (2017-2023)
8.2.2 Forecast Trend (2024-2032)
8.3 Germany
8.3.1 Historical Trend (2017-2023)
8.3.2 Forecast Trend (2024-2032)
8.4 France
8.4.1 Historical Trend (2017-2023)
8.4.2 Forecast Trend (2024-2032)
8.5 Italy
8.5.1 Historical Trend (2017-2023)
8.5.2 Forecast Trend (2024-2032)
8.6 Others
9 Asia Pacific Chronic Inflammatory Demyelinating Polyneuropathy Treatment Market
9.1 Market Share by Country
9.2 China
9.2.1 Historical Trend (2017-2023)
9.2.2 Forecast Trend (2024-2032)
9.3 Japan
9.3.1 Historical Trend (2017-2023)
9.3.2 Forecast Trend (2024-2032)
9.4 India
9.4.1 Historical Trend (2017-2023)
9.4.2 Forecast Trend (2024-2032)
9.5 ASEAN
9.5.1 Historical Trend (2017-2023)
9.5.2 Forecast Trend (2024-2032)
9.6 Australia
9.6.1 Historical Trend (2017-2023)
9.6.2 Forecast Trend (2024-2032)
9.7 Others
10 Latin America Chronic Inflammatory Demyelinating Polyneuropathy Treatment Market
10.1 Market Share by Country
10.2 Brazil
10.2.1 Historical Trend (2017-2023)
10.2.2 Forecast Trend (2024-2032)
10.3 Argentina
10.3.1 Historical Trend (2017-2023)
10.3.2 Forecast Trend (2024-2032)
10.4 Mexico
10.4.1 Historical Trend (2017-2023)
10.4.2 Forecast Trend (2024-2032)
10.5 Others
11 Middle East and Africa Chronic Inflammatory Demyelinating Polyneuropathy Treatment Market
11.1 Market Share by Country
11.2 Saudi Arabia
11.2.1 Historical Trend (2017-2023)
11.2.2 Forecast Trend (2024-2032)
11.3 United Arab Emirates
11.3.1 Historical Trend (2017-2023)
11.3.2 Forecast Trend (2024-2032)
11.4 Nigeria
11.4.1 Historical Trend (2017-2023)
11.4.2 Forecast Trend (2024-2032)
11.5 South Africa
11.5.1 Historical Trend (2017-2023)
11.5.2 Forecast Trend (2024-2032)
11.6 Others
12 Current Scenario Evaluation and Regulatory Framework
12.1 Emerging Therapies and Clinical Trials
12.2 Patent Landscape
12.2.1 Patent Overview
12.2.1.1 Patent Status and Expiry
12.2.1.2 Timelines from Drug Development to Commercial Launch
12.2.1.3 New Drug Application
12.2.1.3.1 Documentation and Approval Process
12.3 Cost of Treatment
12.4 Regulatory Framework
12.4.1 Regulatory Overview
12.4.1.1 US FDA
12.4.1.2 EU EMA
12.4.1.3 INDIA CDSCO
12.4.1.4 JAPAN PMDA
12.4.1.5 Others
13 Challenges and Unmet Needs
13.1 Treatment Pathway Challenges
13.2 Compliance and Drop-Out Analysis
13.3 Awareness and Prevention Gaps
14 Global Chronic Inflammatory Demyelinating Polyneuropathy Treatment Market Dynamics
14.1 Market Drivers and Constraints
14.2 SWOT Analysis
14.3 Porter’s Five Forces Model
14.4 Key Demand Indicators
14.5 Key Price Indicators
14.6 Industry Events, Initiatives & Trends
14.7 Value Chain Analysis
15 Supplier Landscape
15.1 Grifols, S.A.
15.1.1 Company Overview
15.1.2 Product Portfolio
15.1.3 Demographic Reach and Achievements
15.1.4 Mergers and Acquisitions
15.1.5 Certifications
15.2 Octapharma AG
15.2.1 Company Overview
15.2.2 Product Portfolio
15.2.3 Demographic Reach and Achievements
15.2.4 Mergers and Acquisitions
15.2.5 Certifications
15.3 Baxter International Inc.
15.3.1 Company Overview
15.3.2 Product Portfolio
15.3.3 Demographic Reach and Achievements
15.3.4 Mergers and Acquisitions
15.3.5 Certifications
15.4 Pfizer Inc.
15.4.1 Company Overview
15.4.2 Product Portfolio
15.4.3 Demographic Reach and Achievements
15.4.4 Mergers and Acquisitions
15.4.5 Certifications
15.5 CSL Behring LLC
15.5.1 Company Overview
15.5.2 Product Portfolio
15.5.3 Demographic Reach and Achievements
15.5.4 Mergers and Acquisitions
15.5.5 Certifications
15.6 MedDay SA
15.6.1 Company Overview
15.6.2 Product Portfolio
15.6.3 Demographic Reach and Achievements
15.6.4 Mergers and Acquisitions
15.6.5 Certifications
15.7 Shire plc
15.7.1 Company Overview
15.7.2 Product Portfolio
15.7.3 Demographic Reach and Achievements
15.7.4 Mergers and Acquisitions
15.7.5 Certifications
15.8 Takeda Pharmaceutical Company Limited
15.8.1 Company Overview
15.8.2 Product Portfolio
15.8.3 Demographic Reach and Achievements
15.8.4 Mergers and Acquisitions
15.8.5 Certifications
15.9 Teijin Limited
15.9.1 Company Overview
15.9.2 Product Portfolio
15.9.3 Demographic Reach and Achievements
15.9.4 Mergers and Acquisitions
15.9.5 Certifications
15.10 Momenta Pharmaceuticals, Inc.
15.10.1 Company Overview
15.10.2 Product Portfolio
15.10.3 Demographic Reach and Achievements
15.10.4 Mergers and Acquisitions
15.10.5 Certifications
16 Global Chronic Inflammatory Demyelinating Polyneuropathy Treatment Market- Drug Distribution Model (Additional Insight)
16.1 Overview
16.2 Potential Distributors
16.3 Key Parameters for Distribution Partner Assessment
17 Payment Methods (Additional Insight)
17.1 Government Funded
17.2 Private Insurance
17.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
Key Questions Answered in the Report
The market attained a value of USD 3.61 billion in 2021.
The market is expected to rise at a CAGR of 6.90% in the forecast period of 2024-2032 and is anticipated to reach USD 6.91 billion by 2030.
Chronic inflammatory demyelinating polyneuropathy is a rare neuroinflammatory disorder. The destruction of nerve fibre myelin sheaths and inflammation of nerve roots takes place in this disorder.
Based on the therapeutic method, the market is segmented into corticosteroids, intravenous immunoglobulins, plasma exchange, immunotherapy, stem cell transplant, and physical therapy, among others.
The regions are North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa.
Based on the diagnosis, the market is bifurcated into electrodiagnostic testing, nerve conduction, electromyography, spinal fluid analysis and others.
The end-users are hospitals, speciality neurological clinics, and research and academic laboratories.
The increasing prevalence of chronic inflammatory demyelinating polyneuropathy, rising awareness and growing research and development activities are driving the market growth.
North America is anticipated to hold a significant share in the market during the forecast period.
The key companies involved in the market are Grifols, SA, Octapharma AG, Baxter International Inc., Pfizer, Inc., CSL Behring, GE Neuro, MedDay Pharmaceuticals, Shire, Takeda Pharmaceuticals, Teijin Pharma, Momenta Pharmaceuticals, among others.
Purchase Options
Call us on
Purchase Full Report
Mini Report
$ 3499
$1999
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Single User License
$ 5999
$2999
-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Five User License
$ 7999
$3999
-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$ 9999
$5999
-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Why Expert Market Research?
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
NEWSLETTER